Skip to content
Subscriber Only

Merck KGaA Said to Weigh Selling its Allergy Therapy Unit

  • Merck may fetch about 600 million euros from business sale
  • Sale could attract strategic bidders and buyout firms
Updated on

Merck KGaA is considering a sale of its allergy business as the German company seeks to reduce debt following the $17 billion takeover of Sigma-Aldrich Corp., according to people with knowledge of the matter.

The business, known as Allergopharma, may fetch about 600 million euros ($636 million) and could attract interest from drug companies and private-equity firms, the people said, asking not to be identified because the deliberations are private. The process is at an early stage and Merck could still decide against a sale, the people said.